These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1650744)

  • 1. Kinetic analysis of the clotting system in the presence of heparin and depolymerized heparin.
    Heuck CC; Baumann P
    Haemostasis; 1991; 21(1):10-8. PubMed ID: 1650744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computerized analysis of the in vitro activation of the plasmatic clotting system.
    Baumann P; Jürgensen T; Heuck CC
    Haemostasis; 1989; 19(6):309-21. PubMed ID: 2620867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J
    J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation of the extrinsic pathway of the plasmatic clotting system.
    Baumann P; Heuck CC
    Haemostasis; 1991; 21(6):329-37. PubMed ID: 1823878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular weight and biochemical profile of a chemically modified heparin derivative, Suleparoide.
    Callas DD; Ahsan A; Iqbal O; Fareed J
    Thromb Res; 1993 Feb; 69(4):369-76. PubMed ID: 8470058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic and anticoagulant activity of depolymerized fragment of the glycosaminoglycan extracted from Stichopus japonicus Selenka.
    Suzuki N; Kitazato K; Takamatsu J; Saito H
    Thromb Haemost; 1991 Apr; 65(4):369-73. PubMed ID: 1647552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
    Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
    Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide.
    Lormeau JC; Herault JP
    Thromb Haemost; 1993 Feb; 69(2):152-6, 176. PubMed ID: 8384381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of thrombin-receptors of thrombocytes for the interaction of heparins and low-molecular-weight heparin in human whole blood clotting.
    Harenberg J; Schuler M; Zimmermann R; Heptner W
    Haemostasis; 1988; 18 Suppl 3():20-2. PubMed ID: 2840370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
    Ofosu FA
    Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
    Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
    Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor X assays using chromogenic substrate S-2222.
    Girolami A; Saggin L; Boeri G
    Am J Clin Pathol; 1980 Mar; 73(3):400-2. PubMed ID: 7361721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity.
    Béguin S; Kessels H; Dol F; Hemker HC
    Thromb Haemost; 1992 Aug; 68(2):136-42. PubMed ID: 1412157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives.
    Harenberg J; Giese C; Knödler A; Zimmermann R
    Haemostasis; 1989; 19(1):13-20. PubMed ID: 2537786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of low molecular weight heparin on coagulation parameters and bleeding time in healthy volunteers.
    Warning A; Nies D; Wolf H; Welzel D
    Arzneimittelforschung; 1987 Jul; 37(7):847-9. PubMed ID: 2823841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of human mast cell tryptase and eosinophil granule proteins on the kinetics of blood clotting.
    Samoszuk M; Corwin M; Hazen SL
    Am J Hematol; 2003 May; 73(1):18-25. PubMed ID: 12701115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro anticoagulation monitoring of low-molecular-weight heparin.
    Wang JQ; Shi XB; Yang JG; Hu DY
    Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future alternatives to heparin: low-molecular-weight heparin and hirudin.
    Donayre CE; Ouriel K; Rhee RY; Shortell CK
    J Vasc Surg; 1992 Apr; 15(4):675-82. PubMed ID: 1313932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III.
    Baruch D; Lindhout T; Wagenvoord R; Hemker HC
    Haemostasis; 1986; 16(2):71-81. PubMed ID: 3086193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.